Philipp Beckhove

Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany.

MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts.

Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX.

Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ.

Definiens AG is a holding company, which engages in the development and market of biomedical imaging and data analysis software solutions. The firm specializes in the design and manufacture of imaging software suites for drug discovery, development, and diagnostics applications. It engages in the custom image analysis projects for the biopharmaceutical industry, spanning drug discovery, translational research, and clinical research. It offers image analysis processing, integration and deployment, planning, and consulting services. The company was founded by Gerd Binnig in 1994 and is headquartered in Munich, Germany.

BIOCRATES Life Sciences AG operates as a research and technology. It provides metabolic phenotyping services. The firm products are absoluteIDQ p150 kit, p180 kit, sterio17 kit, steroid reagents, biocrates bile acids kit, and steroid kit. The company was founded by Gunther Bonn, Adelbert Roscher, and Hartmut Glossmann in 2002 and is headquartered in Innsbruck, Austria.

Novo Seeds (Novo Seeds) is a venture capital operating division of Novo Nordisk Fonden. The firm was established in 2007, and is headquartered in Hellerup, Denmark.

apceth Biopharma GmbH operates as a contract development & manufacturing organization. The firm specializes in cell-based and gene therapy products (Advanced Therapy Medicinal Products, ATMPs). Its GMP services include quality management, quality control, assay development, process development, cell banking & formulation and project management. The company was founded in 2007 and is headquartered in Munich, Germany.

MIG Verwaltungs AG is a private equity investment firm headquartered in Munich, Germany. It was founded in 2004 by entrepreneurs and financial institutions, to follow up on the success of the venture capital investment vehicles Global Chance Fund and Global Asset Fund, with which MIG's management had been involved.

New England Venture Capital Association, Inc. is a non-profit organization which operates as a catalyst, and advocate, and a resource for the innovation economy. The company is headquartered in Cambridge, MA.

Allergan GI Corp. develops peptide therapeutics for the treatment of gastrointestinal disorders. It provides RM-493 a small-peptide melanocortin-4 receptor agonist, for the treatment of obesity and diabetes, and RM-131 a small-peptide ghrelin agonist, for the treatment of diabetic gastro paresis and other gastrointestinal functional disorders. The company was founded by Bart Henderson and Elizabeth Stoner in 2008 and is headquartered in Madison, NJ.

AMSilk GmbH engages in the production of fiber and biopolymers.It offers implant coating, medical devices for OTC wound care, functional cosmetics, cell biology device kits, biosteel spidersilk fibers and spidersilk research license. It serves the biosteel fibers, medical devices, and cosmetic ingredients industry. The firm's materials are to be applied in numerous fields to improve existing products or to develop materials for completely new applications, which could not be realized until now due to the lack of an appropriate material. The company was founded by Axel H. Leimer, Thomas Scheibel, and Lin Römer in 2008 and is headquartered in Planegg, Germany.

Part of MPM BioImpact, Inc, MPM Asset Management LLC is a company that provides venture capital. The company is based in Boston, MA.

Vie Venture LLC provides real estate services. The American company was founded by Steven St. Peter.

Greater Kansas City Community Foundation provides services for the downtrodden and homeless people. It also offers donor-advised funds. The company was founded by Ed Smith in 1978 and is headquartered in Kansas City, MO.

JDRF T1D Fund (JDRF T1D Fund) is a venture capital subsidiary of JDRF International founded in 2011 by Sean Doherty. The firm is headquartered in Boston, Massachusetts.

Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark.

Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland.

EpiTherapeutics ApS is a holding company that develops cancer drugs based on research in the field of epigenetics. Its development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. The firm's regulation is commonly used for post-translational covalent modifications of histones and other chromatin-remodeling complexes, which determines whether a gene is accessible and hence, expressed or repressed. Its covalent modifications involved in epigenetic regulation include deoxyribonucleic acid methylation, histone acetylation, and histone methylation. The company was founded by Kristian Helin, Paul Andreas Compare Cloos, Jesper Aagaard Christensen, Karl Agger, and Klaus Hansen on September 18, 2008 and is headquartered in Greve, Denmark.